Fintel reports that on January 8, 2025, BTIG downgraded their outlook for Inari Medical (NasdaqGS:NARI) from Buy to Neutral.

BTIG raised the firm’s price target on MoonLake Immunotherapeutics (MLTX) to $81 from $71 and keeps a Buy rating on the shares. The firm ...

Fintel reports that on January 8, 2025, BTIG downgraded their outlook for Palo Alto Networks (NasdaqGS:PANW) from Buy to Neutral. Analyst Price Forecast Suggests 22.11% Upside As of December 23, 2024, ...

After a busy 2024, experts called out competition in soft tissue robotics, uncertainty from a Trump White House and continued ...

Capital One Financial Corp (COF) stock saw a decline, ending the day at $180.14 which represents a decrease of $-1.75 or -0.96% from the prior close of $181.89. The stock opened at $180.45 and touched ...

“In 2025, the energy sector will be less about barrels of oil and more about ... billions of cubic feet of natural gas demand in 2025 and beyond as the technology sector intersects with the energy ...

Carisma Therapeutics, Inc. (NASDAQ:CARM – Get Free Report) has earned an average recommendation of “Hold” from the seven ...

KeyBanc raised the firm’s price target on DoorDash (DASH) to $225 from $180 and keeps an Overweight rating on the shares. The firm says the ...